<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T21:52:47Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/33541" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/33541</identifier><datestamp>2026-02-15T21:28:14Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4953</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Garrison, Louis P</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US" authority="b57e603c-af5b-4af4-8911-7ea5b1979b54" confidence="-1">Pistoresi, Ryan Hay</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2015-09-29T17:56:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2015-09-29T17:56:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2015-09-29</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted" lang="en_US">2015</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">Pistoresi_washington_0250O_14941.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/33541</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Thesis (Master's)--University of Washington, 2015</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Background: Many new disease-modifying therapies (DMTs) have recently been approved for relapsing-remitting multiple sclerosis (RRMS) in the United States. Objective: To assess the values of 10 first-line therapies for RRMS, including generic glatiramer acetate, versus the natural history of disease for a newly diagnosed RRMS patient. Perspective: United States third-party payer. Methods: A Markov model was developed and estimates were made using data on natural history of disease progression, annual relapse rates, medication efficacy, costs, and utilities to determine incremental cost-effectiveness ratios (ICERs). Results: Base case is a cohort of 30-year-old females at Extended Disability Status Scale (EDSS) state 0 at a 20 year time horizon versus the natural history of disease.  Dimethyl fumarate demonstrates the lowest ICER at $895,073/QALY. Conclusions: DMTs for RRMS have low value versus the natural history of disease, and would not be considered cost-effective by conventional standards.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype" lang="en_US">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en_US</dim:field>
   <dim:field mdschema="dc" element="rights" lang="en_US">Copyright is held by the individual authors.</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">cost-effectiveness analysis; cost-utility analysis; ICER; multiple sclerosis; QALYs; relapsing-remitting multiple sclerosis</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">Pharmaceutical sciences</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">Economics</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">Health care management</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other" lang="en_US">to be assigned</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Cost-Utility Analysis of Medications for Relapsing-Remitting Multiple Sclerosis: A United States Third-Party Payer Perspective</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms" lang="en_US">Open Access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>